Your browser doesn't support javascript.
loading
Trajectory of brain-derived amyloid beta in Alzheimer's disease: where is it coming from and where is it going?
Liu, Ni; Haziyihan, Anaer; Zhao, Wei; Chen, Yu; Chao, Hongbo.
Afiliação
  • Liu N; Zhengzhou University, Zhengzhou, 450001, China.
  • Haziyihan A; Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan, 430074, China.
  • Zhao W; Zhengzhou University, Zhengzhou, 450001, China.
  • Chen Y; Zhengzhou University, Zhengzhou, 450001, China.
  • Chao H; Zhengzhou University, Zhengzhou, 450001, China.
Transl Neurodegener ; 13(1): 42, 2024 Aug 19.
Article em En | MEDLINE | ID: mdl-39160618
ABSTRACT
Alzheimer's disease (AD) is a progressive neurological disorder that primarily impacts cognitive function. Currently there are no disease-modifying treatments to stop or slow its progression. Recent studies have found that several peripheral and systemic abnormalities are associated with AD, and our understanding of how these alterations contribute to AD is becoming more apparent. In this review, we focuse on amyloid­beta (Aß), a major hallmark of AD, summarizing recent findings on the source of brain-derived Aß and discussing where and how the brain-derived Aß is cleared in vivo. Based on these findings, we propose future strategies for AD prevention and treatment, from a novel perspective on Aß metabolism.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Peptídeos beta-Amiloides / Doença de Alzheimer Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Peptídeos beta-Amiloides / Doença de Alzheimer Idioma: En Ano de publicação: 2024 Tipo de documento: Article